Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Assessment of tuberculosis drug efficacy using preclinical animal models and in vitro predictive techniques.
NPJ Antimicrob Resist
December 2024
Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA, 98145, USA.
Tuberculosis (TB) killed approximately 1.3 million people in 2022 and remains a leading cause of death from the bacteria Mycobacterium tuberculosis (M.tb); this number of deaths was surpassed only by COVID-19, caused by the SARS-CoV-2 virus.
View Article and Find Full Text PDFItaconate mechanism of action and dissimilation in .
Proc Natl Acad Sci U S A
January 2025
Centre for Tuberculosis Research, Tuberculosis Research Laboratory, Translational Health Science and Technology Institute, National Capital Region Biotech Science Cluster 3rd Milestone, Faridabad, Haryana 121001, India.
Itaconate, an abundant metabolite produced by macrophages upon interferon-γ stimulation, possesses both antibacterial and immunomodulatory properties. Despite its crucial role in immunity and antimicrobial control, its mechanism of action and dissimilation are poorly understood. Here, we demonstrate that infection of mice with increases itaconate levels in lung tissues.
View Article and Find Full Text PDFMicroneedle-mediated intradermal delivery of Bacille Calmette-Guérin (BCG) vaccines for single-dose tuberculosis vaccination.
Tuberculosis (Edinb)
January 2025
Clinical Research Center, Masan National Tuberculosis Hospital, Changwon, 51755, Republic of Korea. Electronic address:
Tuberculosis (TB) remains a highly lethal infectious disease. The primary preventive measure is Bacille Calmette-Guérin (BCG), a live attenuated vaccine. However, the current intradermal vaccination method with 10-dose vials faces challenges such as inadequate infant injection, inaccurate dispensing, and unstable storage.
View Article and Find Full Text PDFEstimating the Early Transmission Inhibition of new treatment regimens for drug-resistant tuberculosis.
J Infect Dis
January 2025
Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA, United States.
Introduction: Most drug-resistant tuberculosis (DR-TB) occurs due to transmission of unsuspected or ineffectively treated DR-TB. The duration of treatment to stop person-to-person spread of DR-TB is uncertain. We evaluated the impact of novel regimens, including BPaL, on DR-TB transmission using the human-to-guinea pig (H-GP) transmission model.
View Article and Find Full Text PDFTuberculosis screening among cough suppressant buyers in pharmacies and drug outlets in Guinea: a cross-sectional study.
BMJ Open Respir Res
December 2024
World Health Organization, Geneva, Switzerland.
Article Synopsis
- Tuberculosis (TB) is a major health issue in Guinea, with many cases going undetected; an intensified case finding strategy involved pharmacies and drug outlets targeting customers buying cough suppressants.
- A study conducted in Conakry involved screening 916 individuals for TB, resulting in a 14% bacteriologically confirmed TB diagnosis, with gender and age influencing diagnosis likelihood.
- The intervention cost approximately $32.66 per person referred and $237.45 for those diagnosed, showing that using pharmacies as a TB detection point is both feasible and effective in boosting detection rates.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!